The gene under investigation in this study, MAL (myelin and lymphocyte protein), has been implicated in several malignancies including esophageal, ovarian and cervical cancers. The MAL protein is involved in apical transport in polarized-epithelial cells and therefore its disruption may lead to the loss of organized polarity, a characteristic of most solid malignancies. Aberrant methylation of gene promoters leading to transcriptional silencing is associated with the onset and progression of cancer. Preliminary data we have accumulated thus far demonstrates that the MAL promoter is frequently hypermethylated in breast cancer but unmethylated in normal breast epithelial cells. In this study we will be investigating the significance and consequences of this finding. Based on our preliminary findings, we hypothesize that MAL promoter hypermethylation blocks the binding of transcriptional regulatory proteins resulting in transcriptional silencing and the disruption of normal biological activities that contribute to breast cancer development and progression.
Specific aim #1 will determine the nature and frequency of hypermethylation in the MAL promoter and whether these methylation events affect gene expression. The main experiments for this aim include bisulfite genomic sequencing, methylation-specific PCR (MSP) and RT-PCR expression analysis following treatment with the methylation inhibitor decitabine.
Specific aim #2 will determine whether methylation silences gene expression by blocking the binding of gene regulatory proteins. We will use chromatin immunoprecipitation analysis to monitor transcription factor binding under varying conditions and luciferase gene expression analysis to observe changes in expression after protein binding.
Specific aim #3 will determine the biological consequences of MAL expression such as changes in cell cycle and apoptosis, and whether methylation affects the biological activity.
Specific aim #4 will assess MAL's use as a biomarker for detection based on the ability to detect MAL promoter methylation in serum from breast cancer patients. Our preliminary data indicate that hypermethylation of MAL is a common event in primary breast cancers and may be a useful marker for detection. Its role in cell polarity may define a new functional class of tumor suppressor genes and thus warrants further study with respect to the development and etiology of cancer. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Predoctoral Individual National Research Service Award (F31)
Project #
5F31GM082048-02
Application #
7500717
Study Section
Minority Programs Review Committee (MPRC)
Program Officer
Gaillard, Shawn R
Project Start
2007-09-01
Project End
2010-08-31
Budget Start
2008-09-01
Budget End
2009-08-31
Support Year
2
Fiscal Year
2008
Total Cost
$40,972
Indirect Cost
Name
Duke University
Department
Biochemistry
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Wang, Xin; Xi, Wen; Toomey, Shaun et al. (2016) Stoichiometry and Change of the mRNA Closed-Loop Factors as Translating Ribosomes Transit from Initiation to Elongation. PLoS One 11:e0150616
Zhang, Chongxu; Wang, Xin; Park, Shiwha et al. (2014) Only a subset of the PAB1-mRNP proteome is present in mRNA translation complexes. Protein Sci 23:1036-49
Zhang, Chongxu; Lee, Darren J; Chiang, Yueh-Chin et al. (2013) The RRM1 domain of the poly(A)-binding protein from Saccharomyces cerevisiae is critical to control of mRNA deadenylation. Mol Genet Genomics 288:401-12
Wang, Xin; Zhang, Chongxu; Chiang, Yueh-Chin et al. (2012) Use of the novel technique of analytical ultracentrifugation with fluorescence detection system identifies a 77S monosomal translation complex. Protein Sci 21:1253-68
Richardson, Roy; Denis, Clyde L; Zhang, Chongxu et al. (2012) Mass spectrometric identification of proteins that interact through specific domains of the poly(A) binding protein. Mol Genet Genomics 287:711-730
Horne, Hisani N; Lee, Paula S; Murphy, Susan K et al. (2009) Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy. Mol Cancer Res 7:199-209